Johnson & Johnson To Undergo third xarelto trial
Judge Orders Janssen and Bayer to Undergo Third Xarelto Trial
July 25, 2017
A federal judge in Louisiana denied a bid by Johnson & Johnson subsidiary Janssen and Bayer HealthCare Pharmaceuticals to dismiss a lawsuit against them, ordering the companies to stand for a third bellwether trial in a Multi-District Litigation (MDL) case against them concerning the alleged health risks of the blood thinner Xarelto.
At issue in the MDL is whether Janssen and Bayer knew but failed to warm doctors and patients about the risk of dangerous internal hemorrhaging that is allegedly linked to Xarelto use.
The plaintiff in the third suit is Dora Mingo, who started taking Xarelto in 2015 to treat a case of deep vein thrombosis that started after a hip replacement surgery. Mingo suffered from gastrointestinal bleeding, and alleges that the drug’s makers knew about this risk but failed to inform doctors and patients about it.
The drugmakers had claimed that they were unable to change the labels of their drugs after the U.S. Food and Drug Administration (FDA) had approved them, but Judge Eldon Fallon dismissed that line of reasoning.
The drugmakers have won the first two bellwether trials; the third is slated to begin on August 7.
If you’ve ever taken Xarelto and have experienced heavy or dangerous bleeding, you may have a case against the drug’s manufacturers. Contact TheLawFirm.com today to learn how we can help you.
Johnson and Johnson Wins Third Lawsuit
Johnson and Johnson Wins Xarelto Lawsuit
Johnson and Bayer Denies Xarelto Risks
Third Xarelto Trial
Xarelto Wants Doctors Testimony Struck
Xarelto Linked to over 2200 Injuries
TheLawFirm.com’s award winning lawyers have been featured in over 50 radio and television interviews including:
Real lawyers, real results!
no recovery, no fee!